Select a medication above to begin.
Imcivree
setmelanotide
Adult Dosing .
Dosage forms: INJ: 10 mg per mL
obesity, Bardet-Biedl syndrome-associated
- [1-3 mg SC qd]
- Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
obesity, POMC deficiency-associated
- [1-3 mg SC qd]
- Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
obesity, PCSK1 deficiency-associated
- [1-3 mg SC qd]
- Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
obesity, LEPR deficiency-associated
- [1-3 mg SC qd]
- Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
renal dosing
- [see below]
- eGFR 15-29: start 0.5 mg qd x2wk, then 1 mg qd x1wk, then incr. to 1.5 mg qd as tolerated; eGFR <15: avoid use
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ: 10 mg per mL
obesity, Bardet-Biedl syndrome-associated
- [2-5 yo, 15-19 kg]
- Dose: 0.5 mg SC qd
- [2-5 yo, 20-29 kg]
- Dose: 1 mg SC qd; Start: 0.5 mg SC qd x2wk
- [2-5 yo, 30-39 kg]
- Dose: 1.5 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk
- [2-5 yo, >40 kg]
- Dose: 2 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk
- [6-11 yo]
- Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to 3 mg SC qd as tolerated; Info: may decr. dose to 0.5 mg SC qd for at least 1wk if 1 mg SC qd not tolerated
- [12 yo and older]
- Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
obesity, POMC deficiency-associated
- [2-5 yo, 15-19 kg]
- Dose: 0.5 mg SC qd; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, 20-29 kg]
- Dose: 1 mg SC qd; Start: 0.5 mg SC qd x2wk; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, 30-39 kg]
- Dose: 1.5 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, >40 kg]
- Dose: 2 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [6-11 yo]
- Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to 3 mg SC qd as tolerated; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 0.5 mg SC qd for at least 1wk if 1 mg SC qd not tolerated
- [12 yo and older]
- Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: for pts w/ variant in POMC gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
obesity, PCSK1 deficiency-associated
- [2-5 yo, 15-19 kg]
- Dose: 0.5 mg SC qd; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, 20-29 kg]
- Dose: 1 mg SC qd; Start: 0.5 mg SC qd x2wk; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, 30-39 kg]
- Dose: 1.5 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, >40 kg]
- Dose: 2 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [6-11 yo]
- Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to 3 mg SC qd as tolerated; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 0.5 mg SC qd for at least 1wk if 1 mg SC qd not tolerated
- [12 yo and older]
- Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: for pts w/ variant in PCSK1 gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
obesity, LEPR deficiency-associated
- [2-5 yo, 15-19 kg]
- Dose: 0.5 mg SC qd; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, 20-29 kg]
- Dose: 1 mg SC qd; Start: 0.5 mg SC qd x2wk; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, 30-39 kg]
- Dose: 1.5 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [2-5 yo, >40 kg]
- Dose: 2 mg SC qd; Start: 0.5 mg SC qd, then incr. by 0.5 mg/day q2wk; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance
- [6-11 yo]
- Dose: 0.5-3 mg SC qd; Start: 1 mg SC qd x2wk, then incr. by 1 mg/day to 3 mg SC qd as tolerated; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 0.5 mg SC qd for at least 1wk if 1 mg SC qd not tolerated
- [12 yo and older]
- Dose: 1-3 mg SC qd; Start: 2 mg SC qd x2wk, then incr. to 3 mg SC qd as tolerated; Info: for pts w/ variant in LEPR gene interpreted as pathogenic, likely pathogenic, or of uncertain significance; may decr. dose to 1 mg SC qd for at least 1wk if 2 mg SC qd not tolerated
renal dosing
- [2-5 yo, <20 kg]
- eGFR <30: avoid use
- HD/PD: not defined
- [2-5 yo, 20-29 kg]
- eGFR 15-29: 0.5 mg qd; eGFR <15: avoid use
- HD/PD: not defined
- [2-5 yo, >30 kg]
- eGFR 15-29: start 0.5 mg qd x2wk, then incr. to 1 mg qd; eGFR <15: avoid use
- HD/PD: not defined
- [6-11 yo]
- eGFR 15-29: start 0.5 mg qd x2wk, then incr. to 1 mg qd; eGFR <15: avoid use
- HD/PD: not defined
- [12 yo and older]
- eGFR 15-29: start 0.5 mg qd x2wk, then 1 mg qd x1wk, then incr. to 1.5 mg qd as tolerated; eGFR <15: avoid use
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- breastfeeding
- eGFR <30 (pts 2-5 yo w/ wt <20 kg)
- eGFR <15 (pts 2 yo and older w/ wt >20 kg)
- caution: eGFR 15-29 (pts 2 yo and older w/ wt >20 kg)
- caution: skin pigmentary lesion, pre-existing
- caution: depression hx
- caution: suicidality hx
Drug Interactions .
Overview
setmelanotide
melanocortin agonist
-
None
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn
- anaphylaxis
- depression
- suicidal ideation
Common Reactions
- injection site rxn
- skin hyperpigmentation, reversible
- vomiting
- nausea
- URI
- headache
- diarrhea
- abdominal pain
- back pain
- melanocytic nevus
- fever
- fatigue
- depression
- spontaneous penile erection
- cough
- arthralgia
- asthenia
- dizziness
- xerostomia
- dry skin
- insomnia
- vertigo
- alopecia
- rigors
- constipation
- influenza-like sx
- muscle spasm
- extremity pain
- rash
- suicidal ideation
- sexual dysfxn
- striae
- aggression
Safety/Monitoring .
Monitoring Parameters
dermatologic exams at baseline, then periodically; s/sx depression, behavior changes, suicidality
Benzyl Alcohol Content
risk of serious, potentially fatal gasping syndrome in neonates and low-birth wt infants; not approved in pts <2 yo
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; wt loss during pregnancy offers no benefit and may cause fetal harm; risk of neonatal gasping syndrome due to benzyl alcohol content; no human data available; no known risk of teratogenicity based on animal data at 11x MRHD
Lactation
Clinical Summary
avoid use while breastfeeding due to benzyl alcohol content; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: catabolism; CYP450: none
Excretion: urine (39% unchanged); Half-life: 11h
Subclass: Inherited Metabolic Disorders ; Obesity/Weight Management: Melanocortin Receptor Agonists
Mechanism of Action
binds and activates melanocortin receptors, reestablishing impaired MC4 receptor pathway activity in brain to regulate appetite and weight control
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.